A particularly interesting aspect was the broad landscape of young biotech companies: many are still in the preclinical phase and are preparing the transition into clinical development. This is precisely the stage at which key questions often arise around GMP structures, regulatory requirements, Qualified Persons and the practical organisation of clinical trial processes.
Konrad exchanged many business cards on site, attended several presentations and systematically engaged in discussions with biotech companies, testing laboratories and CMOs. These conversations once again highlighted how important robust partner structures become once projects move from early research into clinical application.
One special programme highlight was the presentation by FoRx Therapeutics, one of our clients. FoRx is working on precision oncology therapies in the field of DNA replication stress and presented current developments and perspectives at Swiss Biotech Day.
The international nature of the event was also clearly evident, including through delegations from various countries. Particularly interesting was the perspective on innovative countries further afield, such as Australia, and the question of which requirements and support structures are relevant there for export, clinical development and approval.
We return from Basel with valuable technical insights, new contacts and a clearer understanding of the current needs of the biotech community.
Many thanks to the Swiss Biotech Association for organising the event, and to all those who contributed to the open and constructive exchange.
Your Partner in Quality, Safety, and Compliance
The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.
Related services
Related articles
29 May 2026
Learning from mistakes: second workshop on respectful communication in challenging situations
As part of regular internal workshops, we engage with our six company values: professionalism, cooperation, responsibility, trust, respect and appreciation. The central question is what these values mean for our day-to-day collaboration - both within teams across different sites and in our work with customers.
13 May 2026
Strong synergies at this year’s Making Pharmaceuticals exhibition in the UK
A heartfelt thank you to Normec Synergy Health, to Making Pharmaceuticals, and to everyone we had the pleasure of meeting during the event.
26 Mar 2026
Making Pharmaceuticals 2026: PharmaKorell in Coventry with a Focus on AI in the Pharmaceutical Industry
Dr Ulrich Korell, Managing Director and Founder of PharmaKorell, will be representing our company at this year’s Making Pharmaceuticals exhibition in Coventry. Having attended the event as visitors last year, we have decided to exhibit with our own stand this year. You will find us at Stand 306, together with our Normec sister company, Synergy Health.
19 Feb 2026
Meet Normec Synergy Health & PharmaKorell at Making Pharmaceuticals 2026 – Stand 306
Meet Normec Synergy Health and PharmaKorell GmbH at Stand 306 at Making Pharmaceuticals in Coventry on 21–22 April 2026 - two specialised companies within the Normec Group. Our Managing Director and founder, Dr. Ulrich Korell, looks forward to meeting you in person.
09 Apr 2026
PharmaKorell recognized by kununu once again: With strong ratings across key employer dimensions
In 2026, PharmaKorell was once again recognized by kununu. In addition to its repeated recognition as a Top Company, the company received two further distinctions this year: the Top Rated seal for Salary Satisfaction for the second year in a row, and the Top Rated seal for Family Friendliness for the first time. All kununu seals are based on authentic employee reviews and are awarded to only about 3% of employers on kununu in each category. Particularly encouraging is the fact that this recognition is also reflected in the detailed ratings: 94% of employees are satisfied with their salary, and PharmaKorell achieved a score of 4.4 out of 5 in the Salary & Benefits category.